A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

키워드

참고문헌 (26)

1. Zhou W, "East meets West : ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians", Chin J Cancer, 30, pp.287~292 (2011)
2. Zhang YL, "The prevalence of EGFR mutation in patients with non-small cell lung cancer : a systematic review and metaanalysis", Oncotarget, 7, pp.78985~78993 (2016)
3. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
4. Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
5. Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
6. Pao W, "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain", PLoS Med, 2, pp.e73~ (2005)
7. Onitsuka T, "Acquired resistance to gefitinib : the contribution of mechanisms other than the T790M, MET, and HGF status", Lung Cancer, 68, pp.198~203 (2010)
8. Gainor JF, "Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer", J Clin Oncol, 31, pp.3987~3996 (2013)
9. Soria JC, "Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib(IMPRESS) : a phase 3randomised trial", Lancet Oncol, 16, pp.990~998 (2015)
10. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
11. D'Addario G, "Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer(NSCLC) : SAKK protocol 19", 03, 2008, pp.19, 739~745
12. Wu JY, "Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer", Int J Cancer, 126, pp.247~255 (2010)
13. Lee SJ, "Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs", Lung Cancer, 90, pp.261~266 (2015)
14. Paz-Ares LG, "PARAMOUNT : Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer", J Clin Oncol, 31, pp.2895~2902 (2013)
15. Sun JM, "Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer : a biomarker-stratified randomized phase II trial", J Clin Oncol, 33, pp.2450~2456 (2015)
16. 박세훈, "Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations", Cancer Research and Treatment, 47(4), pp.630~637 (2015), 대한암학회[DOI]
17. Tseng YH, "Efficacy of chemotherapy in epidermal growth factor receptor(EGFR)mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor(TKI)", J Chemother, 28, pp.50~58 (2016)
18. Yang CJ, "Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment", Onco Targets Ther, 9, pp.1579~1587 (2016)
19. Sun JM, "Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy", J Thorac Oncol, 6, pp.1392~1399 (2011)
20. Nicolson MC, "Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial", J Thorac Oncol, 8, pp.930~939 (2013)
21. Oxnard GR, "Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer : distinct natural history of patients with tumors harboring the T790M mutation", Clin Cancer Res, 17, pp.1616~1622 (2011)
22. Hata A, "Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptortyrosine kinase inhibitor : Comparison between T790M mutation-positive and mutation-negative populations", Cancer, 119, pp.4325~4332 (2013)
23. Li W, "T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients", Lung Cancer, 84, pp.295~300 (2014)
24. "NCCN clinical practice guidelines in oncology, non-small cell lung cancer (version 3.2017)" (2016)[URL]
25. Khozin S, "Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer", Clin Cancer Res, 23, pp.2131~2135 (2017)
26. Kim ES, "Olmutinib : first global approval", Drugs, 76, pp.1153~1157 (2016)

관련 논문AI추천